Nandini Krishnamoorthy

Dr. Nandini Krishnamoorthy's research explores how immune cells function early in life to maintain tissue health and coordinate responses to infection and inflammation.

Dr. Krishnamoorthy obtained her PhD in immunology at the University of Pittsburgh with Dr Prabir Ray and her thesis research focused on dissecting the role of c-kit on dendritic cells in T cell differentiation. She moved to Brigham and Women’s Hospital Boston to pursue her postdoctoral fellowship in 2013 with Dr. Bruce Levy towards understanding the role of specialized pro-resolving mediators in mitigation allergic inflammation and viral infections. The overarching theme of Dr. Krishnamoorthy’s research has been the identification of pathways that bridge innate and adaptive immune systems during viral infection and allergen exposure. She is a junior faculty at the division of pulmonary and critical care medicine hoping to expand our understanding of resolution of lung inflammation and specifically dissecting mechanism involved in dendritic cell biology and regulatory T cells dysfunction during viral infection.

Education

Ph.D., Immunology – University of Pittsburgh, Pittsburgh, PA, 2008
M.Sc., Life Sciences (Microbiology) – Bharathidasan University, Tamil Nadu, India, 2001

Honors & Awards

Leadership Development Program, Brigham and Women’s Hospital (2024-2025)
Trainee Award, American Association of Immunologists (2015, 2013)
Travel Scholarship, Future of Science Fund, Keystone Symposia (2014)
Trainee Award, American Association of Immunologists (2009)
Best Graduate Student, Department of Medicine, University of Pittsburgh (2007)

Professional Activities

Editorial & Review Service:
Guest Editor, Frontiers in Immunology (2024 invited)
Ad hoc reviewer: American Journal of Respiratory and Critical Care Medicine, Frontiers in Immunology,
Mucosal Immunology, PLoS One, Respiratory Research, Thorax

Research Funding

Principal Investigator: Brigham and Women’s Hospital, Innovation Ignite Grant (2025-2026); Regulatory T Cell
Activation by an LGR6 Receptor Agonism to Treat Asthma.
Principal Investigator: Brigham and Women’s Hospital, Funds to Sustain Research Excellence Grant (2021-
2023); Maternal-neonatal transmission of protective resolution mechanisms for lung inflammation.
Principal Investigator: NIH/NHLBI R56 HL155917-01 (2021–2023); Maternal-neonatal transmission of
protective resolution mechanisms for lung inflammation.
Co-Investigator: NIH/NHLBI R01HL122531-05 (2020–2025); Specialized pro-resolving mediators in asthma
Co-Investigator: NIH/NHLBI 2R01HL122531-05 (2020–2023); Immunometabolic phenotypes in adult severe
asthma and disease progression
Co-Investigator: Bayer (2020–2021); Pulmonary drug development.

Teaching & Mentoring

University of Pittsburgh – Microbial Pathogenesis Laboratory Training, Medical Students (2004)
Brigham and Women’s Hospital (2013–present) – Supervision of research technicians, graduate students, and
postdoctoral and clinical fellows (3–4 hrs/week)
University of Pittsburgh (2006–2013) – Supervision of graduate students and research technicians (2–3
hrs/week)

Invited Presentations

National Academic talks :
Breaching of pulmonary immune homeostasis – Boston University, Boston, MA (2012)
RSV infection disables regulatory T cells – Brigham and Women’s Hospital, Boston, MA (2013)
Novel mechanisms for resolution of type 2 pulmonary inflammation – UT Southwestern, Dallas, TX (2023)
Novel mechanisms for resolution of type 2 pulmonary inflammation-Mass General Hospital, Boston, MA (2023)
Novel mechanisms for resolution of type 2 pulmonary inflammation-UPenn, Philadelphia, PA (2025)

National Meeting Talks :
RSV infection disables Treg cells– Nemacolin Asthma Conference, Nemacolin, PA (2012)
Maresin 1 restrains ILC2s in allergic inflammation– AAAAI, Houston, TX (2015)
Maresin 1/LGR6 axis in RSV inflammation– Pittsburgh International Lung Conference, Pittsburgh, PA (2022)
Specialized pro-resolving mediators: regulators of infection–GRC, Ventura, CA (2022)
Polyunsaturated fatty acids in allergic inflammation – AAAAI, Washington, DC (2024)
Novel Mechanisms for Resolution of Type 2 Pulmonary Inflammation-– AAAAI, Philadelphia, PA (2025)